Cell Therapeutics to Reacquire Rights to Two Anti-Cancer Compounds from Novartis

Cell Therapeutics (NASDAQ: CTIC ) today announced that it has reached an agreement with Novartis to reacquire rights to two anti-cancer compounds -- pixantrone (PIXUVRI®) and paclitaxel poliglumex (Opaxio™). Under the terms of the previous agreement, CTI has been responsible for development and commercialization activities and expenses for both